Based on 1 Wall Street analysts offering 12 month price targets for Alibaba Health Information Technology in the last 3 months. The average price target is HK$4.54 with a high forecast of HK$4.50 and a low forecast of HK$4.50. The average price target represents a 53.29% change from the last price of HK$2.96.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"HK$1","6":"HK$6","2.25":"HK$2.25","3.5":"HK$3.5","4.75":"HK$4.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4.50000012915,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">HK$4.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.5372762,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">HK$4.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.50000012915,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">HK$4.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.25,3.5,4.75,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Jan<br/>2024","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.8,2.930769240703846,3.061538481407692,3.192307722111538,3.3230769628153842,3.4538462035192303,3.584615444223077,3.715384684926923,3.846153925630769,3.976923166334615,4.107692407038462,4.238461647742308,4.369230888446154,{"y":4.50000012915,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.8,2.9336366307692305,3.0672732615384612,3.200909892307692,3.3345465230769227,3.4681831538461534,3.6018197846153845,3.7354564153846153,3.869093046153846,4.002729676923076,4.136366307692308,4.2700029384615386,4.403639569230769,{"y":4.5372762,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.8,2.930769240703846,3.061538481407692,3.192307722111538,3.3230769628153842,3.4538462035192303,3.584615444223077,3.715384684926923,3.846153925630769,3.976923166334615,4.107692407038462,4.238461647742308,4.369230888446154,{"y":4.50000012915,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.54,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4.77,"date":1685059200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.85,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.67,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.55,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.63,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.8,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.84,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.87,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.85,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.46,"date":1709251200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.8,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$4.50

Average Price TargetHK$4.54

Lowest Price TargetHK$4.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

HSBC

xxxxxxxxxxxxx

Reiterated

04/02/24

Sean Wu CFA

Morgan Stanley

HK$5.00

Sell

68.92%

Upside

Reiterated

01/05/24

Analysts Offer Insights on Healthcare Companies: Alibaba Health Information Technology (Other OTC: ALBHF) and Insmed (NASDAQ: INSM)

Chris Lui

Jefferies

HK$8.20

Buy

177.03%

Upside

Reiterated

12/03/23

Buy Rating Affirmed for Alibaba Health on Strong Financials and Strategic Acquisition

Cui Cui

Citi

HK$8.00

Buy

170.27%

Upside

Reiterated

12/01/23

Alibaba Health (241:HK) (BABA) PT Lowered to HK$8 at CitiCiti analyst Cui Cui lowered the price target on Alibaba Health (241:HK) (NYSE: BABA) to HK$8.00 (from HK$9.50) while maintaining a Buy rating.

Leo Y. YOU

CLSA

HK$5.60

Buy

89.19%

Upside

Reiterated

11/30/23

Alibaba Health (241:HK) (BABA) PT Lowered to HK$5.60 at CLSACLSA analyst Leo You lowered the price target on Alibaba Health (241:HK) (NYSE: BABA) to HK$5.60 (from HK$6.40) while maintaining a Buy (1) rating.

Henry Liu, CFA

UBS

HK$5.00

Hold

68.92%

Upside

Reiterated

10/24/23

Alibaba Health (241:HK) PT Lowered to HK$5 at UBSUBS analyst Henry Liu lowered the price target on Alibaba Health (241:HK) to HK$5.00 (from HK$6.50) while maintaining a Neutral rating.

Unknown Analyst

Not Ranked

Macquarie

HK$4.70

Hold

58.78%

Upside

Reiterated

12/01/23

Alibaba Health (241:HK) (BABA) PT Raised to HK$4.70 at MacquarieMacquarie analyst John Wang raised the price target on Alibaba Health (241:HK) (NYSE: BABA) to HK$4.70 (from HK$4.60) while maintaining a Neutral rating.

Best Analysts Covering Alibaba Health Information Technology

Which Analyst Should I Follow If I Want to Buy HK:0241 and Sell After:

1 Month

Leo Y. YOUCLSA

Success Rate

1/2 ratings generated profit

Average Return

+3.10%

reiterated a buy rating 5 months ago

Copying Leo Y. YOU's trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +3.10% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Leo Y. YOUCLSA

Success Rate

1/2 ratings generated profit

Average Return

-16.35%

reiterated a buy rating 5 months ago

Copying Leo Y. YOU's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -16.35% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Charlene LiuHSBC

Success Rate

0/2 ratings generated profit

Average Return

-23.40%

reiterated a buy rating 30 days ago

Copying Charlene Liu's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -23.40% per trade.

2 Years

Charlene LiuHSBC

Success Rate

0/2 ratings generated profit

Average Return

-23.40%

reiterated a buy rating 30 days ago

Copying Charlene Liu's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -23.40% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0241 Analyst Recommendation Trends

Rating

Oct 23

Nov 23

Dec 23

Jan 24

Apr 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0241 has received 2 Buy Ratings, 1 Hold Ratings, and 1 Sell Ratings. 0241 average Analyst price target in the past 3 months is HK$4.54.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0241 Financial Forecast

0241 Earnings Forecast

Next quarter’s earnings estimate for 0241 is HK$0.02 with a range of HK$0.02 to HK$0.02. The previous quarter’s EPS was HK$0.04. 0241 beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 41.32% of the time in the same period. In the last calendar year 0241 has Outperformed its overall industry.

0241 Sales Forecast

Next quarter’s sales forecast for 0241 is HK$13.41B with a range of HK$13.36B to HK$13.45B. The previous quarter’s sales results were HK$14.22B. 0241 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 55.48% of the time in the same period. In the last calendar year 0241 has Outperformed its overall industry.

0241 Stock Forecast FAQ

What is HK:0241’s average 12-month price target, according to analysts?

Based on analyst ratings, Alibaba Health Information Technology Ltd.’s 12-month average price target is HK$4.54.

What is HK:0241’s upside potential, based on the analysts’ average price target?

Alibaba Health Information Technology Ltd. has 53.29% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Alibaba Health Information Technology Ltd. a Buy, Sell or Hold?

Alibaba Health Information Technology Ltd. has a conensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.

What is Alibaba Health Information Technology Ltd.’s share price target?

The average share price target for Alibaba Health Information Technology Ltd. is HK$4.54. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$4.50 ,and the lowest forecast is HK$4.50. The average share price target represents 53.29% Increase from the current price of HK$2.96.

What do analysts say about Alibaba Health Information Technology Ltd.?

Alibaba Health Information Technology Ltd.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of Alibaba Health Information Technology Ltd.?

To buy shares of HK:0241, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Alibaba Health Information Technology (0241) Stock Forecast & Price Target

0241 Analyst Ratings

0241 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alibaba Health Information Technology

0241 Analyst Recommendation Trends

0241 Financial Forecast

0241 Earnings Forecast

0241 Sales Forecast

0241 Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts